Antibody-Mediated Rejection

Antibody-mediated rejection (AMR) is graft injury caused by donor-specific antibodies that bind the graft's vascular endothelium, activate complement, and recruit effector cells. Recognized as a distinct process from cellular rejection, it is a major driver of both acute and chronic allograft loss and is comparatively resistant to standard immunosuppression.

Definition

Antibody-mediated rejection is allograft injury mediated by antibodies, typically donor-specific anti-HLA antibodies, that target graft endothelium and cause microvascular inflammation and damage, diagnosed by a combination of histological microvascular injury, evidence of antibody interaction with the endothelium, and detectable donor-specific antibody.

Scope

This entry covers AMR (also called humoral rejection) as a clinical and pathological entity across solid-organ transplants: its diagnostic triad of microvascular injury, antibody-mediated tissue evidence (such as complement deposition), and donor-specific antibodies, its acute and chronic forms, and its place in classification systems. It is a reference description, not a treatment protocol.

Core questions

• How do donor-specific antibodies injure an allograft?
• What diagnostic criteria distinguish antibody-mediated from T-cell-mediated rejection?
• Why is AMR comparatively resistant to conventional immunosuppression?

Key concepts

• Donor-specific antibodies (DSA)
• Anti-HLA antibodies
• Complement activation and C4d deposition
• Microvascular inflammation (glomerulitis, capillaritis)
• Banff diagnostic criteria for AMR
• Acute versus chronic active AMR

Mechanisms

AMR begins with antibodies, usually directed at donor HLA molecules, binding to the endothelium of the graft microvasculature. Bound antibody can activate the classical complement pathway, leaving deposits such as C4d as a tissue footprint, and can also recruit natural killer cells and macrophages through Fc-receptor engagement, producing microvascular inflammation (glomerulitis and peritubular capillaritis in the kidney). Sustained antibody injury drives chronic microvascular remodeling. Because plasma cells producing antibody are relatively insensitive to T-cell-directed agents, AMR responds poorly to standard immunosuppression.

Clinical relevance

AMR is diagnosed by integrating allograft histology, evidence of antibody-endothelial interaction, and donor-specific antibody testing, and its recognition reshaped transplant pathology and the understanding of late graft loss. Trial evidence on treating established AMR is limited and has often been disappointing, which is itself an important reference point. This entry describes the entity and its evidence and is not a basis for individualized treatment.

Epidemiology

Donor-specific antibodies and antibody-mediated injury are now recognized as leading contributors to late allograft failure, and AMR has been incorporated into classification systems for kidney and, more recently, liver allografts.

History

Humoral rejection was long suspected but hard to prove until the recognition that C4d deposition in graft capillaries marks antibody activity, which, combined with sensitive donor-specific antibody assays, established AMR as a distinct diagnosis. The Banff process progressively formalized criteria for kidney AMR and later extended the concept to other organs such as the liver.

Debates

How effective is treatment of established antibody-mediated rejection?

A randomized trial of bortezomib in late AMR did not demonstrate benefit on key endpoints, and overall the evidence base for treating chronic AMR is weak, leaving optimal management uncertain.

Key figures

• Robert Colvin
• Alexandre Loupy
• Carmen Lefaucheur
• Mark Haas

Seminal works

• colvin-2005
• loupy-2018
• haas-2018

Frequently asked questions

How is antibody-mediated rejection different from acute cellular rejection?

Cellular rejection is driven mainly by T cells infiltrating the graft, whereas antibody-mediated rejection is driven by donor-specific antibodies injuring the graft's blood-vessel lining; they have different histology and respond differently to treatment.

What does C4d staining indicate?

C4d deposition in graft capillaries is a tissue marker of classical complement activation by bound antibody and is one of the features used to support a diagnosis of antibody-mediated rejection.